2-乙基-3-(2-羟基乙基)喹唑啉-4-酮 | 135644-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-乙基-3-(2-羟基乙基)喹唑啉-4-酮
• 英文名称: 2-ethyl-3-(2-hydroxyethyl)quinazolin-4-one
• 英文别名: 2-ethyl-3-(2-hydroxyethyl)quinazolin-4(3H)-one；2-ethyl-3-(2-hydroxyethyl)-3,4-dihydro-4-quinazolinone；2-ethyl-3-(2-hydroxyethyl)quinazoline-4(3H)-one；4(3H)-Quinazolinone, 2-ethyl-3-(2-hydroxyethyl)-
• CAS: 135644-06-3
• 化学式: C₁₂H₁₄N₂O₂
• 分子量: 218.255
• InChiKey: PYUHZORCCAHZHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-乙基-3-(2-羟基乙基)喹唑啉-4-酮 在 溴 、 sodium acetate 、 溶剂黄146 作用下， 反应 4.0h， 以95%的产率得到2-(1-bromoethyl)-3-(2-hydroxyethyl)quinazolin-4-one
  参考文献：
  名称：

  氮桥头化合物。第85部分。3,4-二氢-1 H，6 H [1,4]恶嗪基[3,4- b ]喹唑啉-6-酮的合成和反应性† ‡

  摘要：

  通过不同的途径制备了3，4-二氢-1 H，6 H- [1，4]恶嗪基[3，4- b ]喹唑啉-6-one 3及其1-甲基和1-羟基衍生物8和13。使化合物3的活性亚甲基与电子-羟基试剂（溴，氯化苯基重氮，亚硝酸，Vielsmeier-Haack试剂，芳族醛和草酸二乙酯）反应，生成1-取代的3,4-二氢[1 H， 6 H）-1,4-恶嗪基[3,4- b ]喹唑啉-6-酮。1-羟基和1-溴衍生物13和15的反应性在某些反应中也进行了调查。通过uv，1 H和13 C nmr光谱对3,4-二氢-1 H，6 H- [1,4]恶嗪基[3,4- b ]喹唑啉-6-进行了表征。

  DOI：

  10.1002/jhet.5570300539
• 作为产物：
  描述：

  2-(丙酰基氨基)苯甲酸 在 乙酸酐 作用下， 反应 3.0h， 生成 2-乙基-3-(2-羟基乙基)喹唑啉-4-酮
  参考文献：
  名称：

  氮桥头化合物。第85部分。3,4-二氢-1 H，6 H [1,4]恶嗪基[3,4- b ]喹唑啉-6-酮的合成和反应性† ‡

  摘要：

  通过不同的途径制备了3，4-二氢-1 H，6 H- [1，4]恶嗪基[3，4- b ]喹唑啉-6-one 3及其1-甲基和1-羟基衍生物8和13。使化合物3的活性亚甲基与电子-羟基试剂（溴，氯化苯基重氮，亚硝酸，Vielsmeier-Haack试剂，芳族醛和草酸二乙酯）反应，生成1-取代的3,4-二氢[1 H， 6 H）-1,4-恶嗪基[3,4- b ]喹唑啉-6-酮。1-羟基和1-溴衍生物13和15的反应性在某些反应中也进行了调查。通过uv，1 H和13 C nmr光谱对3,4-二氢-1 H，6 H- [1,4]恶嗪基[3,4- b ]喹唑啉-6-进行了表征。

  DOI：

  10.1002/jhet.5570300539

文献信息

• Synthesis of quinazoin-4-ones through an acid ion exchange resin mediated cascade reaction
  作者：Huiyong Yang、Jun Xu、Yilan Zhang、Lei He、Pengfei Zhang、Wanmei Li

  DOI：10.1039/d0ob00881h

  日期：——

  cascade reaction of N-(2-(4,5-dihydrooxazol-2-yl)phenyl)benzamide in the presence of an acid ion exchange resin is described. In this reaction, a range of substrates bearing various substituent groups are well compatible. This work provides a green and atom-economical alternative approach for the synthesis of quinazolin-4-ones in good yields.

  描述了在酸性离子交换树脂存在下N-（2-（4,5-二氢恶唑-2-基）苯基）苯甲酰胺的有趣的级联反应。在该反应中，具有各种取代基的一系列底物是良好相容的。这项工作提供了绿色和原子经济的替代方法，以高收率合成喹唑啉-4-酮。
• [EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR TRAITER DES TROUBLES ASSOCIÉS AUX RÉCEPTEURS 5-HT1A ET 5-HT2A
  申请人：ACHE LAB FARMACEUTICOS SA

  公开号：WO2012037634A1

  公开（公告）日：2012-03-29

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  这项发明涉及与烷基-哌嗪基苯基4(3H)-喹唑啉酮通式(I)化合物相关，这些化合物在药理学上活跃，并能通过促进对5-HT1A和5-HT2A 5-羟色胺受体的作用来控制、缓解或治疗与这些受体相关的疾病，并且含有这些化合物的药物组合物用于治疗与这些受体相关的疾病。这些化合物及其药物组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、恐慌、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等疾病方面具有用处，这些疾病与这些受体有关。
• Fibrate Compounds Having Ppar Agonist Activity
  申请人：Das Saibal Kumar

  公开号：US20080114005A1

  公开（公告）日：2008-05-15

  There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH 2 —, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARα agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARα agonist activity and a PPARα agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.

  提供了具有PPAR激动剂活性的衍生物。这些衍生物包括化合物和/或其药学上可接受的盐；其中化合物具有公式（I），其中A具有结构（II）或（III）；X选择自—CH2—，—O—，—NH—和—S—；Y选择自—O—，—NH—和—S—；Z可以位于任何取代位置，是氢或卤素；R1和R2，可以相同也可以不同，独立地选择自氢和C1-C8烷基，或者R1和R2共同形成具有4到6个碳原子的碳环；R3选择自氢和C1-C8烷基；R4，R5和R6，可以相同也可以不同，独立地选择自氢和C1-C8烷基；n为1到6。提供了各种实施例和变体。根据其他方面，本发明还提供在哺乳动物中产生PPARα激动剂活性的方法，该方法包括向哺乳动物投与某些第一方面的衍生物的有效量，一种产生PPARα激动剂活性的方法和在哺乳动物中的PPARα激动剂活性，该方法包括向哺乳动物投与某些衍生物的有效量；以及包括第一方面的衍生物和一个或多个药学上可接受的辅料的药物组合物。提供了各种实施例和变体。
• Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors
  申请人：ACHÉ INTERNATIONAL (BVI) LTD.

  公开号：US20140303179A1

  公开（公告）日：2014-10-09

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT 1A and 5-HT 2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯基4（3H）-喹唑啉酮通式（I）化合物，这些化合物具有药理活性，并能够通过促进对5-HT1A和5-HT2A血清素受体的作用，有助于控制、缓解或治愈与这些受体相关的疾病，以及包含这些化合物的制药组合物，用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、惊恐症、精神病、进食和睡眠障碍、强迫症以及女性性功能障碍等与这些受体相关的疾病方面具有用途。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS
  申请人：Freire Torres Russo Valter

  公开号：US20130184286A1

  公开（公告）日：2013-07-18

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯4(3H)-喹唑酮通式(I)化合物，这些化合物具有药理活性，并能够以促进对5-HT1A和5-HT2A血清素受体的作用来控制、缓解或治愈与这些受体相关的疾病，并且包含这些化合物的制药组合物可用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动、惊恐、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等与这些受体相关的其他疾病方面非常有用。